Pfizer Inc. (NYSE:PFE) Shares Acquired by Whittier Trust Co.

Share on StockTwits

Whittier Trust Co. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 571,923 shares of the biopharmaceutical company’s stock after purchasing an additional 14,125 shares during the period. Whittier Trust Co.’s holdings in Pfizer were worth $20,549,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Stephens Inc. AR lifted its stake in Pfizer by 15.9% during the third quarter. Stephens Inc. AR now owns 532,716 shares of the biopharmaceutical company’s stock valued at $19,140,000 after purchasing an additional 72,894 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in Pfizer by 0.4% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 271,720 shares of the biopharmaceutical company’s stock valued at $9,763,000 after purchasing an additional 1,111 shares during the last quarter. Curbstone Financial Management Corp lifted its stake in Pfizer by 0.6% during the third quarter. Curbstone Financial Management Corp now owns 63,763 shares of the biopharmaceutical company’s stock valued at $2,291,000 after purchasing an additional 390 shares during the last quarter. Peoples Bank OH lifted its stake in Pfizer by 9.8% during the third quarter. Peoples Bank OH now owns 6,966 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 624 shares during the last quarter. Finally, Kistler Tiffany Companies LLC lifted its stake in Pfizer by 9.2% during the third quarter. Kistler Tiffany Companies LLC now owns 43,994 shares of the biopharmaceutical company’s stock valued at $1,581,000 after purchasing an additional 3,716 shares during the last quarter. 71.66% of the stock is owned by institutional investors and hedge funds.

In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were bought at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Several research firms recently commented on PFE. UBS Group reissued a “neutral” rating and set a $43.00 target price on shares of Pfizer in a research note on Monday, August 5th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Tuesday, October 1st. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Finally, DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a research report on Wednesday, August 28th. Twelve research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer has an average rating of “Hold” and a consensus target price of $44.47.

Pfizer stock opened at $36.57 on Monday. The firm has a market cap of $201.66 billion, a PE ratio of 12.19, a P/E/G ratio of 2.16 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The firm’s 50 day moving average price is $36.19 and its two-hundred day moving average price is $39.73. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.82 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.94%. Pfizer’s dividend payout ratio is presently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What is a Tariff?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Unique Fabricating Inc  CEO Byrd Douglas Cain III Purchases 4,900 Shares of Stock
Unique Fabricating Inc CEO Byrd Douglas Cain III Purchases 4,900 Shares of Stock
Forrester Research, Inc.  Insider Carrie Johnson Sells 621 Shares of Stock
Forrester Research, Inc. Insider Carrie Johnson Sells 621 Shares of Stock
Modine Manufacturing Co.  VP Matthew J. Mcburney Sells 4,900 Shares of Stock
Modine Manufacturing Co. VP Matthew J. Mcburney Sells 4,900 Shares of Stock
GenMark Diagnostics, Inc  CEO Hany Massarany Sells 7,744 Shares
GenMark Diagnostics, Inc CEO Hany Massarany Sells 7,744 Shares
FS KKR Capital Corp  Insider Brian Gerson Purchases 10,000 Shares
FS KKR Capital Corp Insider Brian Gerson Purchases 10,000 Shares
Claymore CEF GS Connect ETN  Shares Up 10%
Claymore CEF GS Connect ETN Shares Up 10%


© 2006-2019 Ticker Report